Centrexion Therapeutics logo

CNTX - Centrexion Therapeutics Share Price

n/a 0.0  0.0%

Last Trade -

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6431
Unlock CNTX Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2018,Centrexion Therapeutics Corp revenues was not reported. Netloss applicable to common stockholders increased 44% to$28.1M. Higher net loss reflects Research and development -Balancing increase of 24% to $17M (expense), General andadministrative - Balancing increase of 33% to $5.9M(expense), Revaluation of stock warrant liabilitiesdecrease from $339K (income) to $763K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CNTX Revenue Unlock CNTX Revenue

Net Income

CNTX Net Income Unlock CNTX Revenue

Normalised EPS

CNTX Normalised EPS Unlock CNTX Revenue

PE Ratio Range

CNTX PE Ratio Range Unlock CNTX Revenue

Dividend Yield Range

CNTX Dividend Yield Range Unlock CNTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CNTX EPS Forecasts Unlock CNTX Revenue
Profile Summary

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated February 20, 2013
No. of Shareholders: n/a
No. of Employees: 14
Sector Healthcare
Industry Pharmaceuticals
Exchange NASDAQ Global Select Market
Shares in Issue 22,162,604
Free Float (0.0%)
Eligible for
CNTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CNTX
Upcoming Events for CNTX
Frequently Asked Questions for Centrexion Therapeutics
What is the Centrexion Therapeutics share price?

As of , shares in Centrexion Therapeutics are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Centrexion Therapeutics share price performed this year?

Shares in Centrexion Therapeutics are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Centrexion Therapeutics price has moved by % over the past year.

What are the analyst and broker recommendations for Centrexion Therapeutics?

There are no analysts currently covering Centrexion Therapeutics.

When will Centrexion Therapeutics next release its financial results?

Centrexion Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-09-30
What is the Centrexion Therapeutics dividend yield?

Centrexion Therapeutics does not currently pay a dividend.

Does Centrexion Therapeutics pay a dividend?

Centrexion Therapeutics does not currently pay a dividend.

When does Centrexion Therapeutics next pay dividends?

Centrexion Therapeutics does not currently pay a dividend.

How do I buy Centrexion Therapeutics shares?

To buy shares in Centrexion Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Centrexion Therapeutics?

Shares in Centrexion Therapeutics are currently trading at n/a, giving the company a market capitalisation of £n/a.

Where are Centrexion Therapeutics shares listed? Where are Centrexion Therapeutics shares listed?

Here are the trading details for Centrexion Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CNTX
What kind of share is Centrexion Therapeutics?

We were not able to load our ranking data for Centrexion Therapeutics

Is there a Centrexion Therapeutics share price forecast 2020?

We were not able to load any forecast data for Centrexion Therapeutics.

How can I tell whether the Centrexion Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Centrexion Therapeutics. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Centrexion Therapeutics are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Centrexion Therapeutics PE Ratio?

We were not able to find PE ratio data for Centrexion Therapeutics.

Who are the key directors of Centrexion Therapeutics?

Centrexion Therapeutics's management team is headed by:

Jeffrey Kindler - CEO
Sol Barer - CHM
James Campbell - PRE
Randall Stevens - OTH
Andrew Partridge - EVP
Michael Ward - CFO
Peter Hanson - COO
Hongbo Lu - IND
Daniel Mendelson - IND
Sara Nayeem - IND
Arnold Oronsky - IND
Joseph Swedish - IND
Who are the major shareholders of Centrexion Therapeutics?

Here are the top five shareholders of Centrexion Therapeutics based on the size of their shareholding:

Similar to CNTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.